These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14872155)

  • 1. Racial response to angiotensin-converting enzyme therapy in systolic heart failure.
    Dries DJ; Yancy CW; Strong MA; Drazner MH
    Congest Heart Fail; 2004; 10(1):30-3. PubMed ID: 14872155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of race on response to RAAS inhibition.
    Wallace TW; Drazner MH
    Curr Heart Fail Rep; 2005 Aug; 2(2):72-7. PubMed ID: 16036054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
    Prisant LM; Thomas KL; Lewis EF; Huang Z; Francis GS; Weaver WD; Pfeffer MA; McMurray JJ; Califf RM; Velazquez EJ
    J Am Coll Cardiol; 2008 May; 51(19):1865-71. PubMed ID: 18466801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.
    Exner DV; Dries DL; Domanski MJ; Cohn JN
    N Engl J Med; 2001 May; 344(18):1351-7. PubMed ID: 11333991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial differences in the outcome of left ventricular dysfunction.
    Dries DL; Exner DV; Gersh BJ; Cooper HA; Carson PE; Domanski MJ
    N Engl J Med; 1999 Feb; 340(8):609-16. PubMed ID: 10029645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of beta-adrenergic receptor antagonists in the treatment of African Americans with heart failure.
    Yancy CW; Laskar S; Eichhorn E
    Congest Heart Fail; 2004; 10(1):34-7. PubMed ID: 14872156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of race in the pharmacotherapy of heart failure.
    Kalus JS; Nappi JM
    Ann Pharmacother; 2002 Mar; 36(3):471-8. PubMed ID: 11895062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of race in heart failure therapy.
    Yancy CW
    Curr Cardiol Rep; 2002 May; 4(3):218-25. PubMed ID: 11960591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BiDil: primary care physicians first and cardiologist when?
    Matthews GE
    J Natl Med Assoc; 2007 Jun; 99(6):697-9; quiz 700. PubMed ID: 17595944
    [No Abstract]   [Full Text] [Related]  

  • 10. Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Con position.
    Ferdinand KC; Serrano CC; Ferdinand DP
    Curr Hypertens Rep; 2002 Aug; 4(4):311-8. PubMed ID: 12117459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure.
    Taylor JS; Ellis GR
    Am J Cardiovasc Drugs; 2002; 2(6):389-99. PubMed ID: 14727954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of angiotensin-converting enzyme inhibitors to beta-blockers has a distinct effect on hispanics compared with african americans and whites with heart failure and reduced ejection fraction: a propensity score-matching study.
    Eshtehardi P; Pamerla M; Mojadidi MK; Goodman-Meza D; Hovnanians N; Gupta A; Lupercio F; Mazurek JA; Zolty R
    J Card Fail; 2015 Jun; 21(6):448-56. PubMed ID: 25805065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Pro position.
    Cohn JN
    Curr Hypertens Rep; 2002 Aug; 4(4):307-10. PubMed ID: 12117458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction.
    LeJemtel TH; Hochman JS; Sonnenblick EH
    J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):47S-51S. PubMed ID: 7775715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction: heart failure in African Americans.
    Yancy CW
    Congest Heart Fail; 2004; 10(1):12. PubMed ID: 14872152
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
    Ghali JK; Tam SW; Ferdinand KC; Lindenfeld J; Sabolinski ML; Taylor AL; Worcel M; Curry CL; Cohn JN;
    Am J Cardiovasc Drugs; 2007; 7(5):373-80. PubMed ID: 18041162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure management in African Americans: meeting the challenge.
    Durand JB
    J Clin Hypertens (Greenwich); 2004 Apr; 6(4 Suppl 1):42-7. PubMed ID: 15073466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients.
    Dries DL; Strong MH; Cooper RS; Drazner MH
    J Am Coll Cardiol; 2002 Jul; 40(2):311-7. PubMed ID: 12106937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
    Böhm M; Pogue J; Kindermann I; Pöss J; Koon T; Yusuf S
    Eur J Heart Fail; 2014 Mar; 16(3):325-33. PubMed ID: 24464788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is heart failure in African Americans a distinct entity?
    Scott RL
    Congest Heart Fail; 2003; 9(4):193-6. PubMed ID: 12937353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.